Stimulant side effects and inverted-U: Implications for ADHD guidelines

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 3, 2013, Pages 217-221

  Levy, Florence ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

ADHD; CNS stimulants; Default mode; Genetic; Inverted U; Side effects

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ATOMOXETINE; CATECHOL METHYLTRANSFERASE; CENTRAL STIMULANT AGENT; DOPAMINE; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; BRAIN BLOOD FLOW; DNA POLYMORPHISM; DOSE RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; NONHUMAN; PREDICTION; PREFRONTAL CORTEX; REVIEW; UNSPECIFIED SIDE EFFECT;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CATECHOL O-METHYLTRANSFERASE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GUIDELINES AS TOPIC; HUMANS; POLYMORPHISM, GENETIC; PREFRONTAL CORTEX; TIC DISORDERS;

EID: 84880562760     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412450754     Document Type: Review

References (33)

1. Alexander GE, Delong MR and Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience 9: 357-381.
2. American Academy of Child and Adolescent Psychiatry (2007) Practice parameters for the assessment and treatment of children and adolescents with Attention Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry 46: 894-921.
3. American Academy of Pediatrics. Subcommittee on Attention- Deficit/Hyperactivity Disorder and Committee on Quality Improvement (2001) Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108: 1033-1044.
4. Arnsten AFT and Dudley AG (2005) Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoreceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behavioral and Brain Functions 1: 2.
5. Arnsten AFT, Steere JC, Jentsch DJ, et al. (1998) Noradrenergic influences on prefrontal cortical cognitive function: Opposing actions at post-junctional alpha1 versus alpha2-adrenergic receptors. Advances in Pharmacology 42: 764-767.
6. Bellgrove MA, Domschke K, Hawi Z, et al. (2005) The methionine allele of the COMT polymorphism impairs prefrontal cognition in children and adolescents with ADHD. Experimental Brain Research 163: 352-360.
7. Bush G (2010) Attention-Deficit/Hyperactivity Disorder and attention networks. Neuropsychopharmacology 35: 278-300.
8. Castellanos FX, Margulies DS, Kelly C, et al. (2008) Cingulate-precuneus interactions: A new locus of dysfunction in adult attention-deficit/ hyperactivity disorder. Biological Psychiatry 63: 332-337.
9. Castellanos FX, Sonuga-Barke EJ, Scheres A, et al. (2005) Varieties of attention-deficit/hyperactivity disorder-related intra-individual variability. Biological Psychiatry 57: 1416-1423.
10. Cheon K-A, Jun J-Y and Cho D-Y (2008) Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder. International Clinical Psychopharmacology 23: 291-298.
11. Del Campo N, Chamberlain SR, Sahakian BJ, et al. (2011) The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biological Psychiatry 69: e145-e157.
12. Fassbender C, Zhang H, Buzy WM, et al. (2009) A lack of default network suppression is linked to increased distractibility in ADHD. Brain Research 1273: 114-128.
13. Floresco SB, West AR, Ash B, et al. (2003) Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nature Neuroscience 6: 968-973.
14. Froelich TE, Epstein JN, Nick TG, et al. (2011) Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 50: 1129-1139.
15. Gamo NJ, Wang M and Arnsten AFT (2010) Methylphenidate and atomoxetine enhance prefrontal function through α2- adrenergic and dopamine D1 receptors. Journal of the American Academy of Child and Adolescent Psychiatry 49: 1011-1023.
16. Goldman-Rakic PS (1987) Circuitry of primate prefrontal cortex and regulation of behavior by representation memory. In: Mountcastle V, Plum F, and Geiger S (eds) Handbook of Physiology: Volume 1, Section 1, Oxford and New York: Oxford University Press pp.373-417.
17. Grossberg S (1999) Neural models of normal and abnormal behavior: What do schizophrenia, parkinsonism, attention deficit disorder, and depression have in common? Progress in Brain Research 121: 375-406.
18. Gusnard DA and Raichle M (2001) Searching for a baseline: Functional imaging and the resting brain. Nature Reviews Neuroscience 2: 685-694.
19. Gusnard DA, Akbudak L, Shulman GL, et al. (2001) Medial prefrontal cortex and self-referential mental activity: Relation to a default mode of brain function. Proceedings of the National Academy of Sciences of the United States of America 98: 4259-4264.
20. Kereszturi E, Tarnok Z, Bognar E, et al. (2008) Catechol-O-methyl transferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 147(B): 1431-1435.
21. Levy F (2009) Inverted-U effects: Dopamine vs noradrenaline and the dopamine theory. Australian and New Zealand Journal of Psychiatry 43: 101-108.
22. Levy F (2012) Response to Whitely: A caution from the coalface. Australian and New Zealand Journal of Psychiatry 46: 404-406.
23. Mattay VS, Goldberg TE, Fera F, et al. (2003) Catechol-O- methyltransferase val 158-met genotype and individual variation in brain response to amphetamine. Proceedings of the National Academy of Sciences of the United States of America 100: 6186-6191.
24. Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. (2005) Midbrain dopamine and prefrontal function in humans: Interaction and modulation by COMT genotype. Nature Neuroscience 8: 594-596.
25. National Health and Medical Research Council (2012). www.nhmrc.gov.au (accessed March 21 2012)
26. Sagvolden T, Johansen EB, Aase H, et al. (2005) A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD), predominantly hyperactive/impulsive and combined subtypes. Behavioral and Brain Sciences 28: 397-468.
27. Sawaguchi T and Goldman-Rakic PS (1994) The role of D1-dopamine receptors in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed response task. Journal of Neurophysiology 71: 351-358.
28. Singer HS and Minzer K (2003) Neurobiology of Tourette's syndrome: Concepts of neuroanatomic localization and neurochemical abnormalities. Brain & Development 25 Suppl 1: S70-S84.
29. Sonuga-Barke EJ (2002) Psychological heterogeneity in AD/ HD - A dual pathway model of behaviour and cognition. Behavioural Brain Research 130: 29-36.
30. Sonuga-Barke E and Castellanos F (2007) Spontaneous attentional fluctuations in impaired states and pathological conditions: A neurobiological hypothesis. Neuroscience and Biobehaviorial Reviews 31: 977-986.
31. Sprague RL and Sleator EK (1977) Methylphenidate in hyperkinetic children: Differences in dose effects on learning and social behavior. Science 198: 1274-1276.
32. Swanson J, Baler RD and Volkow ND (2011) Understanding the effects of stimulant medications on cognition in individuals with Attention-Deficit Hyperactivity Disorder: A decade of progress. Neuropsychopharmacology 36: 207-226.
33. Tarnok Z, Ronai Z, Gervai J, et al. (2007) Dopaminergic candidate genes in Tourette syndrome: Association between tic severity and 3′ UTR polymorphism of the dopamine transporter gene. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 144B: 900-905.